Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

583

Participants

Timeline

Start Date

March 8, 2012

Primary Completion Date

November 23, 2015

Study Completion Date

April 27, 2016

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Irinotecan Injection [Camptosar]

CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.

DRUG

5-fluorouracil

The 5-FU dosage will remain the standard.

DRUG

Leucovorin

The LV dosage will remain the standard.

Trial Locations (1)

100071

Affiliated Hospital Cancer Center, Academy of Military Medical Sciences (307 Hospital of PLA), Beijing

All Listed Sponsors
lead

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

OTHER

NCT01523431 - Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients | Biotech Hunter | Biotech Hunter